News-Medical.Net on MSN
Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...
Background The PR interval is a ubiquitous parameter available to all clinicians. Studies on associated risk have been ...
News-Medical.Net on MSN
Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...
Background Previous epidemiological studies demonstrated that premature atrial contractions (PACs) and premature ventricular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback